As interest continues to build around multi-cancer early detection, hear what care teams need to know about the technology and the legislative outlook for coverage for this revolutionary testing.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
As interest continues to build around multi-cancer early detection, hear what care teams need to know about the technology and the legislative outlook for coverage for this revolutionary testing. CANCER BUZZ speaks with Anna Howard, principal of Policy Development, Access to and Quality of Care at American Cancer Society – Cancer Action Network, and Jeff Allen, president and CEO of Friends of Cancer Research, about the public health aspects of multi-cancer early detection and current policy/advocacy issues related to this new technology.
Guests
Anna Howard
Principal of Policy Development, Access to and Quality of Care
American Cancer Society Cancer Action Network
“These new tests are really a cutting-edge new technology in the fight against cancer. A lot of research and effort has been given to [understanding] how can we detect cancer sooner because we know that when we detect sooner then the individual has a greater likelihood of surviving that cancer and has more treatment options available to them. So, providing coverage through the [Medicare] Multi-Cancer Early Detection Screening Coverage Act really goes hand in hand with the [Cancer] Moonshot Initiative.”
– Anna Howard
Jeff Allen
President and CEO
Friends of Cancer Research
“If these [multi-cancer early detection] tests do go on to show the ability to improve outcomes for many people with cancer that can be identified earlier and successfully treated then they truly could have a transformative impact on cancer as we know it.”
– Jeff Allen
Resources:
This podcast was created in connection with the education program Multi-Cancer Early Detection: Changes on the Horizon. This project is supported by Exact Sciences.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
